文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

脯氨酰羟化酶抑制促进肝再生而不诱导肿瘤生长

Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth.
PubMed 文献 · Ann Surg · 2017-01-01

该研究在小鼠模型中评估泛PHD抑制剂EDHB对扩大性部分肝切除和门静脉结扎后肝再生及转移瘤生长的影响。结果显示EDHB选择性促进肝再生并增加细胞周期蛋白表达,而不增强转移瘤生长,且药物在肝脏蓄积产生肝保护效应而无全身不良反应。

要点

  • EDHB选择性促进小鼠肝切除和门静脉结扎后的肝再生
  • EDHB不促进结直肠癌肝转移灶的肿瘤生长
  • EDHB及其活性代谢物在肝脏蓄积,无全身不良反应

核心结论

  • 药理学抑制PHD使用EDHB可能代表治疗多发双叶结直肠癌肝转移的一种新颖且安全的策略。

研究设计与样本

  • 研究采用多种小鼠肝再生模型,包括扩大性部分肝切除和门静脉结扎用于多发双叶结直肠癌肝转移,评估泛PHD抑制剂EDHB对肝再生和转移瘤生长的影响。
  • 使用液相色谱-串联质谱分析EDHB的代谢和生物分布。

主要发现

  • EDHB选择性增强部分肝切除和门静脉结扎后的肝再生,并增加细胞周期促进性细胞周期蛋白的表达,而不增强转移瘤生长。
  • 系统给药的EDHB及其活性代谢物3,4-二羟基苯甲酸在肝脏蓄积,选择性诱导肝脏保护效应而非肿瘤组织,且无体液不良反应。

临床怎么用

  • 对于多发双叶结直肠癌肝转移患者,PHD抑制可能作为促进术后肝再生而不刺激肿瘤生长的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to assess whether pharmacological inhibition of hypoxia-inducible transcription factor (HIF)-prolyl hydroxylase enzymes (PHD1, PHD2, and PHD3) is a suitable strategy to stimulate liver regeneration after partial hepatectomy for colorectal liver metastases (CRLM). BACKGROUND: Liver regeneration occurs in a hypoxic environment. PHD1 to PHD3 are molecular oxygen sensors and increasingly considered as putative therapeutic targets. However, little is known about the effect of pharmacological PHD inhibition on tumor expansion, and on liver regeneration after surgical resection. METHODS: Various mouse models of liver regeneration after extended partial hepatectomy and portal vein ligation for multiple bilobar CRLM were applied to assess the effect of the small molecule pan-PHD inhibitor ethyl-3,4-dihydroxybenzoate (EDHB) on liver regeneration and metastatic tumor growth. Metabolism and biodistribution of EDHB were analyzed using liquid chromatography coupled to tandem mass spectrometry. RESULTS: EDHB selectively augmented liver regeneration after partial hepatectomy and portal vein ligation, and increased the expression of cell cycle-promoting cyclin proteins, without enhancing metastatic tumor growth. Systemically administered EDHB and its active metabolite 3,4-dihydroxybenzoic acid accumulated in the liver to selectively induce hepatoprotective effects in the liver, but not in tumor tissue, without humoral adverse effects. CONCLUSIONS: Pharmacological inhibition of PHDs using EDHB might represent a novel and safe strategy in the treatment of multiple bilobar CRLM.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Harnoss JM, Platzer LK, Burhenne J, et al. Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth. Ann Surg. 2017. PMID: 28266966. doi:10.1097/SLA.0000000000001696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。